Blends

AOD-9604 / CJC-1295 / Ipamorelin

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Also known as AOD-9604 + CJC-1295 + Ipamorelin

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

AOD-9604 / CJC-1295 / Ipamorelin is listed in the ezGLP knowledgebase under Blends. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Category: Blends
Routes represented: Subcutaneous (SubQ)
Storage context: Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Published literature

Safety evidence

Serious or important: peptide immunogenicity, aggregation, or impurity concerns.

Route-specific human safety and long-term adverse effects are not established.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With another GH/IGF-axis medicine

Safety flag

Duplicate GH/IGF-axis stimulation may amplify IGF-1 elevation, edema, joint symptoms, and glucose intolerance.

Interaction evidence source

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.